home / stock / knbif / knbif news


KNBIF News and Press, Kane Biotech From 06/23/23

Stock Information

Company Name: Kane Biotech
Stock Symbol: KNBIF
Market: OTC
Website: kanebiotech.com

Menu

KNBIF KNBIF Quote KNBIF Short KNBIF News KNBIF Articles KNBIF Message Board
Get KNBIF Alerts

News, Short Squeeze, Breakout and More Instantly...

KNBIF - Kane Biotech Announces Issuance of Restricted Share Units

WINNIPEG, Manitoba, June 23, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF), (the “Company” or “Kane Biotech”), today announces that it has issued 9,703,809 restricted share units of the Company (“RSUs”) to various directors, officers...

KNBIF - Kane Biotech GAAP EPS of -$0.01, revenue of $0.68M

2023-05-25 17:26:26 ET Kane Biotech press release ( OTCQB:KNBIF ): Q1 GAAP EPS of -$0.01. Revenue of $0.68M (+19.3% Y/Y). For further details see: Kane Biotech GAAP EPS of -$0.01, revenue of $0.68M

KNBIF - Kane Biotech Announces First Quarter 2023 Financial Results

WINNIPEG, Manitoba, May 25, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove m...

KNBIF - Kane Biotech Announces FDA 510(k) Clearance for its coactiv+(TM) Antimicrobial Wound Gel

WINNIPEG, Manitoba, May 25, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech”) announces that on May 24, 2023 it received 510(k) clearance of its coactiv+ ™ Antimicrobial Wound Gel from the U.S. Food and Drug...

KNBIF - Kane Biotech to Release First Quarter 2023 Financial Results on May 25, 2023 - Conference Call to Follow

WINNIPEG, Manitoba, May 18, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove m...

KNBIF - Kane Biotech Announces Fourth Quarter and Full Year 2022 Financial Results

WINNIPEG, Manitoba, April 20, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), today announced its fourth quarter and full year 2022 financial results. Fourth Quarter Financial Highlights Total reve...

KNBIF - Kane grants distribution rights for wound gel to ProgenaCare in US

2023-04-20 12:10:08 ET Kane Biotech ( OTCQB:KNBIF ) said it signed a distribution agreement with ProgenaCare Global for its coactiv+ Antimicrobial Wound Gel in the U.S. wound care market. ProgenaCare will have exclusive distribution rights in the U.S. for Kane's coactiv+ Antimicro...

KNBIF - Kane Biotech Announces Distribution Agreement with ProgenaCare Global for its coactiv+(TM) Antimicrobial Wound Gel

WINNIPEG, Manitoba, April 20, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company”, “Kane” or “Kane Biotech”) announced today that it has signed a distribution agreement with ProgenaCare Global LLC (“ProgenaCare”...

KNBIF - Kane Biotech Announces Additional coactiv+(TM) Animal Health Licensing Agreement

WINNIPEG, Manitoba, April 18, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company”, “Kane” or “Kane Biotech”) announces that it has signed a licensing agreement with Skout’s Honor Pet Supply Company (“Skoutȁ...

KNBIF - Kane Biotech to Release Fourth Quarter and Full Year 2022 Financial Results on April 20, 2023 - Conference Call to Follow

WINNIPEG, Manitoba, April 13, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove...

Previous 10 Next 10